All In Biotech

Free tool

FAERS Monitor: Leqvio

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 214012 or its brand name (Leqvio, Inclisiran Sodium). Reports on generic versions are filed under their own applications.

Reports

8,446

Serious

3,638

43% of reports

Hospitalization

857

Death reported

238

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • arthralgia908
  • myalgia706
  • injection site pain600
  • low density lipoprotein increased529
  • pain in extremity510
  • drug ineffective442
  • fatigue440
  • pain423
  • diarrhoea389
  • dyspnoea375
  • headache330
  • rash299
  • muscle spasms268
  • dizziness251
  • cough248

Reports by year received

View as table
YearReports
20181
20191
20201
202132
2022910
20232,224
20241,909
20251,933
20261,435

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,713 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
low density lipoprotein increasedSignal529182.6167.688,867
myalgiaSignal70610.49.75,999
arthralgiaSignal9085.45.13,352
injection site painSignal6004.94.51,870
pain in extremitySignal5104.34.01,312
muscle spasmsSignal2683.63.2514
coughSignal2482.21.9164
pain4231.71.6129
rash2991.71.589
dyspnoea3751.71.598
diarrhoea3891.51.467
fatigue4401.41.353
headache3301.31.225
dizziness2511.31.113
drug ineffective4420.80.815

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.